Thyroid Cancer Trial, Recruiting NCT04615988 Sponsor: Icahn School of Medicine at Mount Sinai Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT04615988
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a cancer that their oncologist plans to treat next with a type of immunotherapy drug that targets PD-1 or PD-L1, where that drug is the only immunotherapy being used (a separate group of 25 people also needs to be planned for treatment with both an anti-PD-1/PD-L1 drug and an anti-CTLA-4 drug combined)
  • People who are willing to complete symptom questionnaires throughout the study
  • People who are willing to have blood drawn as part of the study
  • People who are able to give informed consent to take part
  • People who are 18 years of age or older

Who may not be able to join:

  • People who have a history of overactive or underactive thyroid, whether it caused symptoms or was detected without symptoms
  • People whose blood hemoglobin (a measure of red blood cell health) is below 9 (confirm with trial site for units and context)
  • People who are unable to attend all required study visits
  • People who are currently taking vitamin D supplements specifically to treat a vitamin D deficiency (taking a standard multivitamin that contains vitamin D does not disqualify someone)
  • People who are currently pregnant or breastfeeding
  • People who have a history of hypophysitis (inflammation of the pituitary gland, a small gland at the base of the brain)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Philip Friedlander, MD PhD, MOUNT SINAI HOSPITAL

Phone: 2128248588

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
9 June 2021
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with risk of developing autoimmune thyroid disease treated with single agent.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov